Healthcare Stocks

Haleon IPO: GSK gets shareholders' nod; all you should know

 Haleon IPO: GSK gets shareholders' nod; all you should know

Highlights:,GSK Plc on Wednesday received approval from the shareholders for the demerger of its consumer healthcare arm.,The new entity, called Haleon, will be listed on the London Stock Exchange on 18 July.,In what will be the largest listing on the,Lon...

Read More...
Should you buy AstraZeneca (LON: AZN) shares now?

Should you buy AstraZeneca (LON: AZN) shares now?

Highlights While the FTSE 100 index was trading in red on 7 April, AstraZeneca shares were up after the announcement of its phase three Champion-MG trial results. According to the results, Ultomiris has exhibited long-term efficacy in adults su...

Read More...
AstraZeneca, GSK, Medica: Are healthcare stocks doing well now?

AstraZeneca, GSK, Medica: Are healthcare stocks doing well now?

Highlights Healthcare stocks have gained a lot of investor attention during the pandemic phase. UK healthcare companies, such as AstraZeneca and GlaxoSmithKline, are adapting to the changing environment very quickly and many of them have bright...

Read More...
Is OKYO Pharma (LON: OKYO) going for a Nasdaq listing?

Is OKYO Pharma (LON: OKYO) going for a Nasdaq listing?

Highlights OKYO Pharma is aiming to get its ADSs listed on Nasdaq and has submitted a registration statement with the US SEC for the same. The exclusive book-running manager for the IPO is the California-based investment banking firm ThinkEquit...

Read More...
GlaxoSmithKline (LON: GSK) to start a new business era with Haleon

GlaxoSmithKline (LON: GSK) to start a new business era with Haleon

Highlights GlaxoSmithKline Plc has come one step closer to the proposed demerger of its consumer healthcare business by announcing the name of the new entity. The proposed demerger will be a milestone in the company’s history which was fi...

Read More...
AstraZeneca (AZN) predicts higher sales in 2022: Should you buy now?

AstraZeneca (AZN) predicts higher sales in 2022: Should you buy now?

Highlights  London’s FTSE100 index was in a buoyant mood on 10 February after it saw third day of gains in a row. The total revenues of AstraZeneca increased by 41% to $37,417 million in 2021, and it has raised its 2022 sales forecas...

Read More...
GlaxoSmithKline (GSK) shares: Are they worth your attention?

GlaxoSmithKline (GSK) shares: Are they worth your attention?

British pharmaceutical giant GlaxoSmithKline Plc (LON: GSK) is back in the news after the company reported robust results for the year 2021 before the structured disposal of its consumer healthcare division. The company reported a 9% hike in its ad...

Read More...
GlaxoSmithKline (GSK) settles case with Gilead: Should you buy now?

GlaxoSmithKline (GSK) settles case with Gilead: Should you buy now?

The UK-based pharmaceutical company, GlaxoSmithKline Plc (LON: GSK), which is into research and development of medicine and consumer healthcare products, announced that one of its investment companies, ViiV Healthcare, which is jointly owned with P...

Read More...
Pod Point (PODP) & BP: 2 FTSE stocks to supercharge your portfolio

Pod Point (PODP) & BP: 2 FTSE stocks to supercharge your portfolio

Highlights  FairCharge, a national EV-related campaign, called on the UK treasury to stop the unfair VAT policy levied on EVs when they are charged from public charging points. Public charging VAT currently stands at 20 per cent, while dom...

Read More...
Sareum (SAR) & Hemogenyx (HEMO): 2 LSE pharma stocks to buy today

Sareum (SAR) & Hemogenyx (HEMO): 2 LSE pharma stocks to buy today

Pharma and biotech-focused companies have seen huge investments after the onset of the pandemic. The UK received record levels of investment into its life sciences sector in 2021, with VC (Venture Capital) and PE (Private Equity) investment into th...

Read More...
GSK and Unilever’s offer:  What shareholders can gain?

GSK and Unilever’s offer:  What shareholders can gain?

Highlights The consumer health business of GSK received multiple takeover bids, including a £50 billion bid just before Christmas in 2021 by consumer-goods giant, Unilever Plc. Unilever Plc’s cash and shares offer was rejected as it...

Read More...